|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Jeffrey Marc Leiden||Exec. Chairman||4,75M||19,14M||1956|
|Mr. Michael J. Parini||Exec. VP & Chief Admin., Legal and Bus. Devel. Officer||1,61M||3,28M||1975|
|Mr. Amit K. Sachdev||Exec. VP & Chief Patient Officer||1,16M||9,02M||1968|
|Mr. Stuart A. Arbuckle||Exec. VP & Chief Commercial Officer||1,59M||4,45M||1966|
|Dr. Reshma Kewalramani||Former EVP of Global Medicines Devel. & Medical Affairs, Chief Medical Officer and Director||N/D||N/D||1973|
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for the treatment of cystic fibrosis (CF). The company markets TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF who have specific mutations in their CF transmembrane conductance regulator gene. It is also developing VX-814, which is in Phase II clinical trial and VX-864 that is in Phase I clinical trial for the treatment of alpha-1 antitrypsin deficiency; VX-147 for treating kidney diseases; and CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases. In addition, the company develops VX-150, an inhibitor that is in Phase II clinical trial for acute, neuropathic, and musculoskeletal pain; and VX-561, a potentiator that is in Phase II clinical development; as well as evaluating VX-121, an additional corrector. It sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. The company has collaborations with CRISPR Therapeutics AG; Kymera Therapeutics Inc.; Parion Sciences, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc.; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; X-Chem, Inc.; Molecular Templates, Inc.; and Ribometrix, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
L'ISS Governance QualityScore di Vertex Pharmaceuticals Incorporated al 4 dicembre 2019 è 8. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 7; retribuzione: 8.